Evidence
What peptide studies actually show, which claims remain unproven, and how the regulatory record affects access. Each review gives a direct answer, the evidence behind it and the limits that matter when comparing treatments.
47 reviews · page 4 of 4
What supports Semax as a nootropic, and what is its United States posture?
A drug's standing in Russia is not an approval here. Four trial-type records exist, all published in Russian between 1997 and 2018, none in the English-language literature, and none tests cognitive enhancement in healthy people; Drugs@FDA holds no application under the name.
Has BPC-157 ever been tested in a human clinical trial?
Not in a controlled trial. Four name variants searched in August 2026 returned 230 papers and none under the clinical-trial publication type; the only human reports PubMed indexes are three small uncontrolled studies from one clinic, covering 30 people.
Why did CJC-1295 leave Category 2 in September 2024, and what is its status now?
Its nominators withdrew the nomination, so the FDA removed it from the prohibition category without adding it to Category 1; the compound sits on no list, and no lawful compounding route exists.
Why was DSIP the only peptide the July 2026 committee refused to recommend?
The panel voted against listing on a reported 6–7 with one abstention, and the record it was reading contains no identified gene, precursor protein, or receptor after nearly fifty years, alongside a human literature of a few small studies whose most recent entry dates from 1992.
Is injectable glutathione established for skin lightening, and what has the FDA said about it?
No trial supports it. Seven clinical trials pair glutathione with skin lightening and all seven were read: six test an oral, buccal, or topical preparation, and the seventh tests a four-ingredient injectable for under-eye pigment. The injected route returns no clinical trial at all.
What did the one randomized controlled trial of ipamorelin find?
It missed. In 114 patients after bowel resection, median time to a first tolerated meal was 25.3 hours on ipamorelin against 32.6 on placebo, a difference at p equal to 0.15, and the authors report no significant difference in the key or secondary analyses.
What human evidence exists for KPV?
None. Four name variants return 97 indexed papers and no record at all under the clinical-trial or randomized-trial publication types, while the parent hormone searched the same way in the same session returns 86 clinical trials and 48 randomized ones.
Do the nicotinamide riboside and nicotinamide mononucleotide trials support intravenous NAD+?
No. Those trials tested oral precursors. Counted separately, nicotinamide riboside has 42 clinical trials and nicotinamide mononucleotide 22, while the phrase set naming an infused NAD+ preparation returns 22 papers in total and one relevant randomized trial, in heart failure.
Does sermorelin produce the effects attributed to growth hormone therapy?
Not on this record. Sermorelin reliably raises growth hormone, but the adult trials that measured what a reader cares about are three studies from the 1990s that disagree with each other, and no clinical trial of the molecule has been published since 2005.
Does the published thymosin beta-4 research apply to the compound sold as TB-500?
No. TB-500 is a seven-residue fragment of a 43-residue protein, and the clinical record belongs to the protein. Searched on its own names, TB-500 returns one record under the clinical-trial publication type, and that record is a study of tuberculosis.
Does the evidence behind tesamorelin's approval support general fat loss?
No. Every trial the approval rests on enrolled adults with HIV-associated lipodystrophy, and the one randomized trial of body composition outside that population reduced visceral fat while leaving subcutaneous fat statistically unchanged, at p equal to 0.40.
A review argues from the ledger; the ledger itself is published as reference tables, and every molecule’s dated posture is in the molecule index. Terms of art are defined in the glossary.